A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Clinical trial NCT05255601 · TERMINATED

Trial details

NCT number: NCT05255601
Sponsor: Bristol-Myers Squibb
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Hodgkin Disease

Start date: 2022-09-13
Primary completion: 2025-12-03
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.